Clinical trials recruiting for Endometrial cancer

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
  NCT07189871 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
  NCT06305962 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
  NCT07557225 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Beta-only IL-2 ImmunoTherapY Study
  NCT05086692 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 27 locations
• A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
  NCT07623369 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 9 locations
• A Phase 1 Study of LNCB74 in Advanced Solid Tumors
  NCT06774963 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
  NCT07109726 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 36 locations
• A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
  NCT06695845 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 56 locations
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
  NCT04657068 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 164 locations
• A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
  NCT06738966 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
  NCT06999187 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
  NCT05377996 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• A Study of GV20-0251 in Advanced or Refractory Solid Tumors
  NCT07106827 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
  NCT06172478 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 90 locations
• A Study of MGC026 in Participants With Advanced Solid Tumors
  NCT06242470 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 36 locations
• A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
  NCT06547840 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Female · 7 locations
• A Study of MT-4561 in Patients With Various Advanced Solid Tumors
  NCT06943521 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
  NCT07383506 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
  NCT06395519 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations
• A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
  NCT05208762 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 62 locations
• A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
  NCT07227168 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
  NCT04104776 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 160 locations
• A Study of a Weight Loss Intervention in People With Endometrial Cancer
  NCT06751589 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: Female · 7 locations
• A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
  NCT06028724 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
  NCT07612891 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
  NCT07610798 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
  NCT07371663 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Assessing Uterine Cancer Risk in Lynch Syndrome Carriers Using Vaginal Self-sampling and a Health Questionnaire
  NCT07194551 · Phase: Not applicable (e.g. observational or device study) · Ages: 30 Years and older · Sex: Female · 1 location
• Avera Cancer Sequencing and Analytics Protocol (ASAP)
  NCT05142033 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• Cancer Loyalty Card Study 2 (CLOCS-2)
  NCT06447064 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Comprehensive Outcomes for After Cancer Health
  NCT05349227 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• DESTINY-PANTUMOUR04
  NCT07124000 · Phase: Not specified · Ages: 18 Years to 130 Years · Sex: All (male and female) · 36 locations
• Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction
  NCT06096688 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Distance-Based Exercise to Preserve Function and Prevent Disability
  NCT07059884 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
  NCT06239194 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial
  NCT07227077 · Phase: Not applicable (e.g. observational or device study) · Ages: 65 Years and older · Sex: All (male and female) · 2 locations
• EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
  NCT07262619 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer
  NCT07397624 · Phase: Not specified · Ages: 21 Years to 75 Years · Sex: Female · 2 locations
• Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
  NCT05983432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 117 locations
• Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers
  NCT06800612 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Integrated Cancer Repository for Cancer Research
  NCT02012699 · Phase: Not specified · Ages: 19 Years to 110 Years · Sex: All (male and female) · 84 locations
• Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome
  NCT07220239 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · 1 location
• Molecular Classification in Relation to Prevention of Endometrial Cancer Recurrence and Lifestyle Factors
  NCT06680791 · Phase: Not specified · Ages: No age limits stated · Sex: Female · 1 location
• Navigation Intervention for Adolescent and Young Adult Cancer Survivors
  NCT07406087 · Phase: Not applicable (e.g. observational or device study) · Ages: 21 Years to 45 Years · Sex: All (male and female) · 1 location
• ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
  NCT05542407 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Female · 1 location
• Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
  NCT06293898 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy
  NCT06024109 · Phase: Not specified · Ages: 18 Years and older · Sex: Female · 2 locations
• Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
  NCT05856981 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
  NCT06218914 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
  NCT07327489 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients
  NCT03787056 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 51 locations
• Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
  NCT05579366 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 66 locations
• Robotic-assisted Versus Conventional Laparoscopic Surgery in Obese Patients With Early Endometrial Cancer
  NCT05974995 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• SL-28 for Advanced Solid Tumours
  NCT07341737 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
  NCT03452774 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 204 locations
• Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
  NCT05799274 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Single cEll pRofiling PErsistaNce To ImmuNothErapy
  NCT06680739 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
  NCT00005095 · Phase: Not specified · Ages: 18 Years to 80 Years · Sex: Female · 1 location
• Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
  NCT07444814 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• Study of AVZO-021 in Patients With Advanced Solid Tumors
  NCT05867251 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
  NCT05489211 · Phase: Phase 2 · Ages: 18 Years to 130 Years · Sex: All (male and female) · 96 locations
• Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
  NCT06974110 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
  NCT07524322 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
  NCT04969315 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · 154 locations
• Tirzepatide in Obesity-Driven Endometrial Cancer
  NCT07065552 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: Female · 1 location
• Trop2-targeted immunoPET Imaging of Solid Tumors
  NCT06851663 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
  NCT05366881 · Phase: Not specified · Ages: 40 Years and older · Sex: All (male and female) · 17 locations

Related conditions

Trials recruiting for Endometrial cancer often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Endometrial cancer trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.